GlobeNewswire·Apr 14, 2026, 8:00 AM ET

Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay

IMDX

Insight Molecular Diagnostics (iMDx) will present positive real-world head-to-head data on its GraftAssure assay at the EFI2026 conference in Edinburgh, Scotland, from April 21–24, 2026.
Three posters regarding GraftAssure will be presented at the 63rd ERA Congress in Glasgow, Scotland, from June 3–6, 2026.
A favorable real-world evidence poster will be presented at the American Transplant Congress (ATC) in Boston, Massachusetts, from June 20–24, 2026.
iMDx submitted its GraftAssureDx kit to the FDA on March 25, 2026, under the Class II de novo pathway, marking the first kitted dd-cfDNA assay submitted for regulatory review.
The company announced a preliminary unaudited first quarter 2026 cash balance of $29.4 million, including $24.6 million in net proceeds from a February registered direct financing.
iMDx recognized $32,000 in laboratory services revenue for the first quarter of 2026, while the company remains in a "pre-revenue" status regarding its strategic goal of selling diagnostic test kits.
CEO Josh Riggs and CFO Andrea James will host a fireside chat & one-on-one meetings at the Needham Virtual Healthcare Conference on April 15, 2026.
iMDx plans to drive participation in the GALACTIC registry study & promote the use of GraftAssureIQ, a research-use-only version of its assay, during upcoming conferences.
The company's product portfolio includes GraftAssureCore (LDT), GraftAssureIQ (RUO), & GraftAssureDx (IVD kit in development) for quantifying donor-derived cell-free DNA (dd-cfDNA).